Altered interrelationship of dopamine, prolactin, thyrotropin and thyroid hormone in schizophrenic patients

  • Marie Luise Rao
  • Gisela Gross
  • Gerd Huber
Article

Summary

Increased dopaminergic activity has been postulated to be one of the main causes of schizophrenia. To evaluate this hypothesis further, the interrelation between dopamine, prolactin, thyrotropin (TSH) and l-thyroxine was studied by determining their concentrations in the serum of ten acutely ill schizophrenic patients exhibiting distinct stages of process activity and ten healthy subjects. The level of dopamine was elevated in the sera of schizophrenic patients, whereas the levels of prolactin, TSH and l-thyroxine were decreased. On the basis of these results we hypothesize that 1. increased dopaminergic activity affects pituitary secretory function, and 2. decreased β-adrenergic activity may be a consequence of decreased thyroid hormone concentration in plasma.

Key words

Schizophrenia Serum Dopamine Thyrotropin l-Thyroxine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Axelrod J, Tomchick J (1958) Enzymatic-o-methylation of epinephrine and other catechols. J Biol Chem 233:702–705Google Scholar
  2. Banerjee SP, Kung LS (1977) Beta-adrenergic receptors in rat heart: Effect of thyroidectomy. Eur J Pharmacol 43:207–208Google Scholar
  3. Bennet GW, Sharp T, Brazell M, Marsden CA (1983) TRH and catecholamine neurotransmitter release in the central nervous system. In: Griffiths EC, Bennet GW (eds) Tyrotropin-releasing leasing hormones. Raven Press, New York, pp 253–269Google Scholar
  4. Berger B, Tassin JP, Blanc B, Moyne MA, Thierry AM (1974) Histochemical confirmation for dopaminergic innervation of the rat cerebral cortex after destruction of the noradrenergic ascending pathways. Brain Res 81:332–337Google Scholar
  5. Brown MJ, Jenner DA (1981) Novel double-isotope technique for enzymatic assay of catecholamines, permitting high precision, sensitivity and plasma sample capacity. Clin Sci 61:591–598Google Scholar
  6. Ciaraldi T, Marinetti GV (1977) Thyroxine and propylthiouracil effects in vivo on alpha and beta adrenergic receptors in rat heart. Biochem Biophys Res Commun 74:984–991Google Scholar
  7. Crow TJ, Baker HF, Cross AJ, Joseph MH, Lofthouse R, Longden A, Owen F, Riley GJ, Glover V, Killpack WS (1979) Monoamine mechanisms in chronic schizophrenia: Post-mortem neurochemical findings. Br J Psychiatr 134:249–256Google Scholar
  8. Fujita K, Ito T, Maruta K, Teradaira R, Beppu H, Nakagami Y, Kato Y, Nagutso T, Kato T (1978) Serum dopamine ß-hydroxylase in schizophrenic patients. J Neurochem 30:1569–1572Google Scholar
  9. Haracz JL (1982) The dopamine hypothesis: An overview of studies with schizophrenic patients. Schizophr Bull 8:438–469Google Scholar
  10. Hartmann E (1976) Schizophrenia: A theory. Psychopharmacology 49:1–15Google Scholar
  11. Hoffman BB, Lefkowitz RJ (1980) Radioligand binding studies of adrenergic receptors: New insights into molecular and physiological regulation. Ann Rev Pharmacol Toxicol 20:521–608Google Scholar
  12. Huber G (1966) Reine Defektsyndrome und Basisstadien endogener Psychosen. Fortschr Neurol Psychiatr 34:409–426Google Scholar
  13. Huber G (1972) Klinik und Psychopathologie der organischen Psychosen. In: Kisker KP, Meyer JE, Müller C, Strömgren E (Hrsg) Psychiatrie der Gegenwart. Forschung und Praxis, 2. Aufl, Bd II/2. Springer, Berlin Heidelberg New York, S 71–146Google Scholar
  14. Huber G (1976) Indizien für die Somatosehypothese bei den Schizophrenien, Fortschr Neurol Psychiatr 44:77–94Google Scholar
  15. Huber G (1981) Psychiatrie. Systematischer Lehrtext für Studenten und Ärzte. 3. Aufl. Schattauer, Stuttgart New YorkGoogle Scholar
  16. Huber G (1983a) Das Konzept substratnaher Basissymptome und seine Bedeutung für Theorie und Therapie schizophrener Erkrankungen. Nervenarzt 54:23–32Google Scholar
  17. Huber G (1983b) Newer concepts of basic disorders and basic symptoms in endogenous psychoses: Introduction. Symposion at the VIIth World Congress of Psychiatry, Vienna 1983. In: Berner P (ed) The state of an art. Plenum Press, London (in press)Google Scholar
  18. Huber G, Penin H (1968) Klinisch-elektroencephalographische Korrelationsuntersuchungen bei Schizophrenen. Fortschr Neurol Psychiatr 36:641–659Google Scholar
  19. Huber G, Gross G, Schüttler R (1979) Schizophrenie. Eine verlaufsund sozialpsychiatrische Langzeitstudie. Monographien aus dem Gesamtgebiete der Psychiatrie, Bd 21. Springer, Berlin Heidelberg New YorkGoogle Scholar
  20. Ingbar SH, Woeber KA (1981) The thyroid gland. In: Williams RH (ed) Textbook of Endocrinology, 6th ed. Saunders, Philadelphia, pp 117–248Google Scholar
  21. Johnstone EC, Crow TJ, Mashiter K (1977) Anterior pituitary hormone secretion in chronic schizophrenia—an approach to neurohumoral mechanisms. Psychol Med 7:223–228Google Scholar
  22. Kleinman JE, Weinberger DR, Rogol AD, Bigelow LB, Klein ST, Gillin JC, Wyatt RJ (1982) Plasma prolactin concentrations and psychopathology in chronic schizophrenia. Arch Gen Psychiatr 39:655–657Google Scholar
  23. Langer G, Sachar EJ, Gruen PH (1978) Prolactin response to neuroleptic drugs in normal and schizophrenic subjects. Psychopharmacol Bull 14:8–12Google Scholar
  24. Leblanc H, Lachelin GCL, Abu-Fadil S, Yen SSC (1976) Effect of dopamine infusion on pituitary hormone secretion in humans. J Clin Endocrinol Metab 43:668–674Google Scholar
  25. Loosen PT, Wilson IC, Prange AJ jr (1980) Endocrine and behavioral changes in depression after thyrotropin-releasing hormone (TRH). J Affect Disord 2:267–278Google Scholar
  26. Mackay AVP, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Snyder SH (1982) Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatr 39:991–997Google Scholar
  27. Marschner I, Wood WG, van Thiel D, Habermann J, König A, Scriba PC (1983) Vergleich dreier Ringversuche zur radioimmunologischen Thyrotropin-Bestimmung nach dem „Münchener Modell”. J Clin Chem Clin Biochem 21:301–311Google Scholar
  28. Martin JB, Reichlin S, Brown GM (1977) Clinical neuroendocrinology. Contemporary neurology series. Davies, PhiladelphiaGoogle Scholar
  29. Massara F, Camanni F, Belforte L, Molinatti GM (1976) Dopamine induced inhibition of prolactin on growth hormone secretion in acromegaly. Lancet I:485Google Scholar
  30. Meltzer HY, Busch D, Young M, Tricou BJ, Nasr SJ, Metz J, Fang V (1980a) Prolactin and growth hormone studies in schizophrenic patients and normal controls. In: Brambilla F, Racagni G, de Wied D (eds) Progress in Neuroendocrinology. Elsevier, Amsterdam New York Oxford, pp 283–294Google Scholar
  31. Meltzer HY, Nasr SJ, Tong C (1980b) Serum dopamine-,β-hydroxylase activity in schizophrenia. Biol Psychiat 15:781–788Google Scholar
  32. Patel YC, Alfoerd FP, Burger HG (1972) The 24-hour plasma thyrotrophin profile. Clin Sci 43:71–77Google Scholar
  33. Penin H. Gross G, Huber G (1982) Elektroenzephalographischpsychopathologische Untersuchungen in Basisstadien endogener Psychosen. In: Huber G (Hrsg) Endogene Psychosen: Diagnostik, Basissymptome und biologische Parameter. Schattauer, Stuttgart New York, pp 247–264Google Scholar
  34. Peuler JD, Johnson GA (1977) Simultaneous single isotope radio-enzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci 21:625–636Google Scholar
  35. Prange AJ jr, Wilson IC (1972) Thyrotropin releasing hormone (TRH) for the immediate relief of depression. Psychopharmacology 26:82–84Google Scholar
  36. Prange AJ jr, Loosen PT, Wilson IC, Meltzer HY, Fang VS (1979) Behavioral and endocrine responses of schizophrenic patients to TRH (Protirelin). Arch Gen Psychiatr 36:1086–1093Google Scholar
  37. Quijada M, Illner P, Krulich L, McCann SM (1973) The effect of catecholamines on hormone release from anterior pituitaries and ventral hypothalami incubated in vitro. Neuroendocrinology 13:151–163Google Scholar
  38. Reichlin S (1981) Neuroendocrinology. In: Williams RH (ed) Textbook of Endocrinology, 6th ed. Saunders, Philadelphia, pp 589–645Google Scholar
  39. Schneider K (1980) Klinische Psychopathologie. 12. Aufl, Thieme, StuttgartGoogle Scholar
  40. Smith CK, Barish J, Correa J, Williams RH (1972) Psychiatric disturbance in endocrinologic disease. Psychosom Med 1:69–86Google Scholar
  41. Thierry AM, Blanc G, Sobel A, Stinus L, Glowinski J (1973) Dopaminergic terminals in the rat cortex. Science 182:499–501Google Scholar
  42. Whybrow PC, Prange AJ (1981) A hypothesis of thyroid-catecholamine-receptor interaction. Arch Gen Psychiatr 38:106–113Google Scholar
  43. Wyatt RJ, Bigelow LB, Gillin JC (1979) Catecholamine related substances and schizophrenia: A review. In: Usdin E, Kopin IJ, Barchas JD (eds) Catecholamines: Basic and clinical frontiers. Pergamon Press, New York, pp 1820–1825Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • Marie Luise Rao
    • 1
  • Gisela Gross
    • 1
  • Gerd Huber
    • 1
  1. 1.Psychiatrische Klinik und Poliklinik der Universität BonnBonn 1 (Venusberg)Germany

Personalised recommendations